Intervention not reported
Serious adverse events for all placebos · patients with mental health disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Serious adverse events (6 to 12 months) · people with acute HBV infection
1 finding from 1 review
Adverse events (proportion) (12 months) · people with acute HBV infection
It is very uncertain whether lamivudine changes adverse events (proportion) (12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events (serious adverse events) · children (aged 6 to 11 years) being overweight or obese
The intervention showed no clear difference in adverse events (serious adverse events) (low certainty).
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
No evidence of a difference for any other adverse event (nausea, vomiting, chilling, headache, lacrimation, dysphasia, weakness, nervousness, rhinitis, blurred vision, urinary frequency, dizziness, palpitation, skin…
Studies not reported
GRADE not reported
Adverse events associated with treatment · Adults with oropharyngeal cancer
1 finding from 1 review
Adverse events: grade 2+ treatment-related events similar (31/34 radiotherapy vs 33/34 surgery; RR 0.94, 0.83 to 1.06); more hearing loss/neutropenia/constipation/tinnitus with radiotherapy, more oral bleeding/trismus…
1 study · 68 participants
Very low
Adverse events associated with treatment · Adults with oral cavity cancer (tongue or floor of mouth) and clinically negative neck nodes
Elective neck dissection (at time of primary tumour resection) probably leads to higher adverse events associated with treatment compared with therapeutic (delayed) neck dissection (moderate certainty).
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity cancer
1 finding from 1 review
Adverse events (BHNCSG 1998): flap necrosis, wound infection, fistula, vascular rupture, haematoma, seroma, chyle fistula; no complications in 45/76 modified radical ND and 54/72 supraomohyoid ND; 2 vs 1 postoperative…
1 study · 148 participants
Low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity cancer (tongue or floor of mouth) and clinically negative neck nodes
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: significant difference in complication rates, lower for supraomohyoid (SOND 13.0% vs MRND 21.9%, P=0.040). UW-QOL at 1 year: supraomohyoid superior in pain relief (78.8% vs 75.2%, P=0.013) and shoulder…
1 study · 332 participants
Very low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: severe acute effects in both groups (subcutaneous fibrosis, telangiectasia, moderate-to-severe oedema, xerostomia, trismus, dysphagia); subcutaneous fibrosis more prevalent with surgery + radiotherapy…
1 study · 35 participants
Very low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer with nodal disease (stage N2 or N3)
1 finding from 1 review
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Maternal Grade 3/4 Severe Adverse Events · HIV‐infected mothers and their breastfeeding infants
It is very uncertain whether an extended ZDV/3TC/LPV/r regimen administered to mothers changes maternal Grade 3/4 Severe Adverse Events compared with short course ZDV (intrapartum ZDV/3TC/sdNVP) (very low certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: death (secondary outcome) compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Doubling serum creatinine · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether steroids changes adverse events: doubling serum creatinine compared with no specific treatment (very low certainty).
1 finding from 1 review